Differences in the tumor microenvironment between African-American and European-American breast cancer patients

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Martin, Damali N ^a   Boersma, Brenda J ^a   Yi, Ming ^b   Reimers, Mark ^c   Howe, Tiffany M ^a   Yfantis, Harry G ^d   Tsai, Yien Che ^b   Williams, Erica H ^a   Lee, Dong H ^d   Stephens, Robert M ^b   Weissman, Allan M ^b   Ambs, Stefan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CHLORPROMAZINE; ESTROGEN RECEPTOR; INTERFERON; MESSENGER RNA; RAPAMYCIN; RESVERATROL;

ADULT; AFRICAN AMERICAN; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL INFILTRATION; CHEMOTAXIS; COMPUTER MODEL; CONTROLLED STUDY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MACROPHAGE; MAJOR CLINICAL STUDY; MICROENVIRONMENT; NUCLEOTIDE SEQUENCE; PREVALENCE; RACE DIFFERENCE; TUMOR VASCULARIZATION;

EID: 84887212459     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004531     Document Type: Article

References (55)

1. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, et al. (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56: 168-183.
2. Jatoi I, Becher H, Leake CR (2003) Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system. Cancer 98: 894-899.
3. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, et al. (2006)Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24: 1342-1349.
4. Elledge RM, Clark GM, Chamness GC, Osborne CK (1994) Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86: 705-712.
5. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, et al. (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97: 439-448.
6. Amend K, Hicks D, Ambrosone CB (2006) Breast cancer in african-american women: differences in tumor biology from European-american women. Cancer Res 66: 8327-8330.
7. Hayanga AJ, Newman LA (2007) Investigating the phenotypes and genotypes of breast cancer in women with African ancestry: the need for more genetic epidemiology. Surg Clin North Am 87: 551-68.
8. Porter PL, Lund MJ, Lin MG, Yuan X, Liff JM, et al. (2004) Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 100: 2533-2542.
9. Shavers VL, Harlan LC, Stevens JL (2003) Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 97: 134-147.
10. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
11. Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, et al. (2007) Molecular breast cancer subtypes in premenopausal and postmenopausal african-american women: age-specific prevalence and survival. J Surg Res 143: 109-118.
12. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, et al. (2008) Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 68: 927-936.
13. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
14. Lin EY, Pollard JW (2004) Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 90: 2053-2058.
15. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254-265.
16. Graw J (2003) The genetic and molecular basis of congenital eye defects. Nat Rev Genet 4: 876-888.
17. Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, et al. (2007) The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat Med 13: 1504-1509.
18. Gupta S, Joshi K, Wig JD, Arora SK (2007) Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol 46: 792-797.
19. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
20. Jackson FL (2008) Ancestral links of Chesapeake Bay region African Americans to specific Bight of Bonny (West Africa) microethnic groups and increased frequency of aggressive breast cancer in both regions. Am J Hum Biol 20: 165-173.
21. Bild AH, Potti A, Nevins JR (2006) Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 6: 735-741.
22. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 11-22.
23. Calogero RA, Cordero F, Forni G, Cavallo F (2007) Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Res 9: 211.
24. Curran EM, Judy BM, Duru NA, Wang HQ, Vergara LA, et al. (2006) Estrogenic regulation of host immunity against an estrogen receptor-negative human breast cancer. Clin Cancer Res 12: 5641-5647.
25. Degols G, Eldin P, Mechti N (2007) ISG20, an actor of the innate immune response. Biochimie 89: 831-835.
26. Hurgin V, Novick D, Werman A, Dinarello CA, Rubinstein M (2007) Antiviral and immunoregulatory activities of IFN-gamma depend on constitutively expressed IL-1alpha. Proc Natl Acad Sci U S A 104: 5044-5049.
27. Brodsky LI, Wahed AS, Li J, Tavis JE, Tsukahara T, et al. (2007) A novel unsupervised method to identify genes important in the anti-viral response: application to interferon/ribavirin in hepatitis C patients. PLoS ONE 2: e584.
28. Walser TC, Rifat S, Ma X, Kundu N, Ward C, et al. (2006) Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 66: 7701-7707.
29. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, et al. (2007) CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 104: 15735-15740.
30. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, et al. (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203: 2201-2213.
31. Storey JD, Madeoy J, Strout JL, Wurfel M, Ronald J, et al. (2007) Gene-expression variation within and among human populations. Am J Hum Genet 80: 502-509.
32. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, et al. (2008) Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet 82: 631-640.
33. Jones BA, Kasl SV, Howe CL, Lachman M, Dubrow R, et al. (2004) African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 101: 1293-1301.
34. Borresen-Dale AL (2003) TP53 and breast cancer. Hum Mutat 21: 292-300.
35. Akli S, Keyomarsi K (2004) Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res 6: 188-191.
36. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, et al. (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380.
37. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, et al. (2006) Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66: 5549-5554.
38. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ (2007) Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 26: 611-621.
39. Garvin S, Ollinger K, Dabrosin C (2006) Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231: 113-122.
40. Le Corre L, Chalabi N, Delort L, Bignon YJ, Bernard-Gallon DJ (2005) Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res 49: 462-471.
41. Lee MS, Johansen L, Zhang Y, Wilson A, Keegan M, et al. (2007) The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res 67: 11359-11367.
42. Gil-Ad I, Shtaif B, Levkovitz Y, Nordenberg J, Taler M, et al. (2006) Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. Oncol Rep 15: 107-112.
43. Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, et al. (2007) Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 120: 796-805.
44. Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, et al. (2007) A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 122: 1324-1332.
45. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
46. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567-6572.
47. Yi M, Horton JD, Cohen JC, Hobbs HH, Stephens RM (2006) Whole-PathwayScope: a comprehensive pathway-based analysis tool for highthroughput data. BMC Bioinformatics 7: 30.
48. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
49. Dupont WD, Plummer WD Jr (1998) Power and sample size calculations for studies involving linear regression. Control Clin Trials 19: 589-601.
50. Dupont WD, Plummer WD Jr (1990) Power and sample size calculations. A review and computer program. Control Clin Trials 11: 116-128.
51. Guinee DG, Travis WD, Trivers GE, DeBenedetti VM, Cawley HM, et al. (1995) Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis 16: 993-1002.
52. Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, et al. (2005) Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 11: 232-241.
53. Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, et al. (2000) Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 6: 2408-2416.
54. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
55. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, et al. (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/ glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64: 830-835.